Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -6455.53%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-6455.53%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Compass Therapeutics, Inc.
Market Cap
$172.99M
EBITDA Margin
-6455.53%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.04M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
Market Cap
$174.17M
EBITDA Margin
-144.16%
TTM Avg
-87.79%
3Y Avg
-115.19%
5Y Avg
-149.65%
Market Cap
$176.96M
EBITDA Margin
-83.89%
TTM Avg
-252.72%
3Y Avg
-1380.70%
5Y Avg
-1383.45%
Market Cap
$179.70M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$162.82M
EBITDA Margin
-3676.90%
TTM Avg
-2033.97%
3Y Avg
-1569.70%
5Y Avg
-1569.70%
Market Cap
$184.12M
EBITDA Margin
-6.19%
TTM Avg
-12.15%
3Y Avg
-13.37%
5Y Avg
-13.97%
Market Cap
$153.84M
EBITDA Margin
-550.97%
TTM Avg
-275.49%
3Y Avg
-275.49%
5Y Avg
-275.49%
Market Cap
$192.97M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | $172.99M | -6455.53% | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -416.41% | -228.13% | -163.44% | -116.60% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -144.16% | -87.79% | -115.19% | -149.65% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -83.89% | -252.72% | -1380.70% | -1383.45% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -3676.90% | -2033.97% | -1569.70% | -1569.70% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -6.19% | -12.15% | -13.37% | -13.97% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -550.97% | -275.49% | -275.49% | -275.49% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-6455.5%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-06-30 | -1715.18% |
